Key Takeaways Abbott's (ABT) Established Pharmaceuticals Division ("EPD") has remained a steady growth driver, delivering above 7% sales growth for the past several quarters. In the first quarter of 2026, the top line increased 9%, supported by broad-based momentum across the markets. Excluding foreign exchange impacts, Key Emerging Markets sales grew 9.4%, led by double-digit growth in several countries across the Latin America and Asia Pacific regions. Other Emerging Markets sales increased 7.9% in the qu ...